Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.49 |
| ▸ | CA1 | P00915 | 3/20 | 0.49 |
| ▸ | CA2 | P00918 | 3/20 | 0.49 |
| ▸ | CA9 | Q16790 | 3/20 | 0.49 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.45 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.42 |
| ▸ | ABCC1 | P33527 | 2/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | MITF | O75030 | 1/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL429693 | 0.83 | CA12 (0.50) | CA12CA1CA2CA9TBXA2R | |
| SCHEMBL10002291 | 0.81 | CA12 (0.56) | CA12CA1CA2CA9TBXA2R | |
| SCHEMBL10002281 | 0.78 | CA12 (0.53) | CA12CA1CA2CA9TBXA2R | |
| SCHEMBL8259009 | 0.75 | CA12 (0.48) | CA12CA1CA2CA9ABCB1 | |
| SCHEMBL11148691 | 0.72 | ABCB1 (0.49) | CA12CA1CA2CA9TBXA2R | |
| SCHEMBL14390889 | 0.70 | ABCB1 (0.42) | CA12CA1CA2CA9TBXA2R | |
| SCHEMBL10222404 | 0.70 | ABCB1 (0.42) | CA12CA1CA2CA9TBXA2R | |
| SCHEMBL10002287 | 0.70 | CA12 (0.51) | CA12CA1CA2CA9TBXA2R | |
| SCHEMBL2405742 | 0.69 | CA12 (0.53) | CA12CA1CA2CA9TBXA2R | |
| SCHEMBL10002285 | 0.69 | CA12 (0.53) | CA12CA1CA2CA9TBXA2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2376461-B1 | NITRIC OXIDE FUROXAN DERIVATIVE COMPOUNDS ENDOWED WITH ANTITUMORAL ACTIVITY | HUMANITAS MIRASOLE SPA (IT) | 2015-03-11 | — | — | EP | disclosed |
| US-8592464-B2 | Nitric oxide furoxan derivative compounds endowed with antitumoral activity | HUMANITAS MIRASOLE S.P.A. (IT) | 2013-11-26 | — | — | US | disclosed |
| US-20120021007-A1 | NITRIC OXIDE FUROXAN DERIVATIVE COMPOUNDS ENDOWED WITH ANTITUMORAL ACTIVITY | ISTITUTO ONCOLOGICO VENETO IRCCS (IT) | 2012-01-26 | — | — | US | disclosed |
| EP-2376461-A1 | NITRIC OXIDE FUROXAN DERIVATIVE COMPOUNDS ENDOWED WITH ANTITUMORAL ACTIVITY | Humanitas Mirasole S.p.A. (IT) | 2011-10-19 | — | — | EP | disclosed |
| WO-2010081877-A1 | NITRIC OXIDE FUROXAN DERIVATIVE COMPOUNDS ENDOWED WITH ANTITUMORAL ACTIVITY | HUMANITAS MIRASOLE S.P.A. (IT) | 2010-07-22 | — | — | WO | disclosed |
| WO-2010081488-A1 | NITRIC OXIDE FUROXAN DERIVATIVE COMPOUNDS ENDOWED WITH ANTITUMORAL ACTIVITY | HUMANITAS MIRASOLE S.P.A. (IT) | 2010-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120021007-A1 | NITRIC OXIDE FUROXAN DERIVATIVE COMPOUNDS ENDOWED WITH ANTITUMORAL ACTIVITY | NOS2, NOS1, NOS3 | CA12 3227/4885CA1 3241/4885CA2 1866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.